IRVINE, Calif.--(BUSINESS WIRE)-- #patientsafety--Registration for the 10th Annual Patient Safety, Science & Technology Summit is now closed.
EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees
BURLINGTON, Ontario--(BUSINESS WIRE)--Anaergia Inc. (“Anaergia” or the “Company”) (TSX: ANRG) announced today that one of its subsidiaries, Rialto Bioenergy Facility, LLC (“RBF”), initiated voluntary Chapter 11 restructuring proceedings in the U.S. Bankruptcy Court for the Southern District of California. RBF is 51% owned by Anaergia’s wholly owned subsidiary, Anaergia Services, LLC. RBF anticipates that, during the restructuring proceeding, it will continue to operate its state-of-the-art, mul
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $KONEF #psychedelics--Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its subsidiary KGK Science Inc. (“KGK” or the “Subsidiary”) will participate at the upcoming Nutrition Industry Association
NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy.
OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV.VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce that an existing customer has placed an order sized at 400% of its normal monthly order volume. Based in Southeast Asia, the long-establis
TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, announces the appointment of Dr. Eric Hoskins to the Company’s Board of Directors. Effective at the same time was the resignation of Donal Carroll from the Board of Directors. Dr. Hoskins is
TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced its financial and operating results for the three months ended March 31, 2023 and the grant of stock options (“Options”). All figures are in Canadian dollars, unless otherwise noted. Financial and Operational Highlights Strong quarterly total revenue of $16.1 million for the three months ended Marc
NEW YORK & TORONTO--(BUSINESS WIRE)--Scientists at Klick Labs have developed a new way to catch the earliest signs the human body is failing to control blood glucose levels, before it reaches prediabetic levels in patients. In findings published today in Mayo Clinic Proceedings: Digital Health, researchers outlined a new method of analysis that flags a precursor to prediabetes called impaired glucose homeostasis (IGH). When they applied their patented mathematical method to data obtained from c
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced a CA$701 million co-investment with the Governments of Canada and British Columbia to build new capabilities and infrastructure to develop innovative antibody-based medicines and strengthen Canada’s leadership in clinical research, manufacturing, and drug development. Over the next eight years, AbCellera plans to invest CA$401 million in the project, and the Governments of Canada and British Columbia will con
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that the first participants have been dosed with CYB004 in its ongoing three-part Phase 1 clinical trial evaluating intravenous N,N-dimethyltryptamine (“IV DMT”) and CYB004 in healthy volunteers. As expected, robust psychedeli
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the United States Patent and Trademark Office (“USPTO”) has published patent claims for ATI-1501 under the U.S. Application No. 18/072,154 filed on November 30, 2022 and titled “Oral Formulations of Metronidazole and Methods of Treating an Infection Using Same”. T
NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed will present preclinical data of MM-402, the Company’s proprietary form of R-MDMA, in a model for autism spectrum disorder.
DUBLIN--(BUSINESS WIRE)--IPS-Integrated Project Services, LLC, a leading provider of engineering, procurement, construction management, and validation (EPCMV) services, congratulates WuXi Biologics Ireland Limited (WuXi Biologics) for receiving a Facility of the Year Award (FOYA) from The International Society for Pharmaceutical Engineering (ISPE) in the Operations category for their Large-Scale Manufacturing Facility in Mullagharlin, Dundalk, Ireland. The IPS team of experts provided a range o
BOSTON--(BUSINESS WIRE)--Care Access Expands to Nova Scotia to Increase Clinical Research Access for Underrepresented Canadian Communities.
SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--Veristat Taps Accomplished Industry Leaders to Support Growth and Innovation
MONTREAL--(BUSINESS WIRE)--Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor (CB1r) blockers to address complications associated with metabolic and fibrotic diseases, today announced positive results from a proof-of-concept study of INV-202 in a mouse model of obese asthma at the American Thoracic Society (ATS) International Conference taking place from May 19-24, 2023, in Washington, D.C. In an oral presentation, Carolyn R. Morris, PhD, Facult
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, has announced new research results detailing the development of novel psilocin prodrug derivatives targeting treatment of mental health disorders. A manuscript describing the research has been submitted for peer-reviewed publication and
